ILMN Illumina, Inc.

What a fantastic six months it’s been for Illumina. Shares of the company have skyrocketed 126%, hitting $273.47. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

REGN vs. ILMN: Which Stock Is the Better Value Option?

Investors need to pay close attention to ILMN stock based on the movements in the options market lately.

A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold.

Key Stats for Illumina StockCurrent Price: $273. 90Target Price (Mid): ~$412Street Target: ~$203Potential Total Return: ~50%Annualized IRR: ~10% / yearWhat Happened?Illumina (ILMN) closed at $273.

Index removal puts Illumina in focus Illumina (ILMN) has been removed from the Russell Small Cap Value Index, an index reshuffle that can prompt mechanical selling and raise fresh questions about how the stock is being valued today. The index removal comes at a time when Illumina’s momentum is already strong, with a 1-day share price return of 7.25%, a 30-day share price return of 21.82% and a year-to-date share price return of 103.87%. These feed into a 1-year total shareholder return of...

ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.

There's a joke on Wall Street that analysts never saw an S&P 500 stock they didn't like. Well, that doesn't seem to be the case now.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 38.9% over the past six months, topping the S&P 500 by 20.9 percentage points.

Key TakeawaysYear-Long Surge: Illumina stock has climbed 133% over the past year, closing at $240 on September 18, 2026, up from roughly $103 twelve months earlier. Street Split: Illumina stock carries 7 buy ratings, 4 outperforms, 6 holds, 3 underperforms and 1 sell, and the $203 mean target now sits 15% below where shares trade, a reversal from a year ago when the target sat above the price.

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

Three new names are entering the S&P 500, swapping out brewers and homebuilders for fuel-cell technology and genomics, but whether that trade actually benefits VOO holders depends on a math problem most investors overlook.

The Morning Bull - US Market Morning Update Wednesday, Sep, 16 2026 US stock futures are pointing slightly higher in early trade, with E-mini S&P 500 contracts up about 0.3% and tech heavy Nasdaq futures ahead roughly 0.4%. The big driver is the US 10 year government bond yield, which briefly touched 5.01% before easing to 4.96%. That is the highest level since 2007 and means borrowing costs for mortgages, credit cards, and companies remain expensive. At the same time, rising government bond...

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 93 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Upg

Catherine Clay, CEO of S&P Dow Jones Indices, discusses the upcoming S&P reconstitution and rebalance, noting that the process is fully transparent and routine. She says market participants already know which names are entering and leaving the index, including Bloom Energy, Illumina and Everpure joining the S&P this month, and have ample time to adjust portfolios accordingly. She speaks with Romaine Bostick & Tyler Kendall on "The Close."

Illumina stock is joining the S&P 500 on Sept. 21. Here's why that matters, what's fueling growth, and what investors should watch next.

Everpure stock is joining the S&P 500 on Sept. 21. Here's what's changing, why it matters, and what's driving Everpure's growth this year.

The S&P 500 is set for another shakeup, with Bloom Energy (BE), Everpure (P), and Illumina (ILMN) all joining in the next quarterly rebalancing near the end of September.

A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

Shares of Bloom Energy are surging on the news that the company is set to join the S&P 500.

Bloom Energy is set to join the S&P 500 before trading begins on September 21.

BOTZ offers diversified exposure to a robotics boom fueled by AI, humanoid robots and industrial automation, as the sector rapidly evolves.

Illumina and Everpure also join the S&P 500 in the September rebalance

Bloom Energy has secured a spot in the S&P 500 as part of its quarterly rebalancing.

AI stocks rise despite the market’s inflation worries, but Amgen falls following Swiss drugmaker Novartis’ disappointing trial data.

Investing.com -- U.S. stock futures fell early Tuesday, kicking off a shortened trading week as Wall Street monitored the U.S.-Iran conflict alongside rising trade tensions between Canada and the U.S. Futures tied to the Dow Jones Industrial Average fell 0.8% by 05:30 ET (09:30 GMT). S&P 500 futures fell 0.3% and Nasdaq-100 futures slipped 0.1%. U.S. markets were closed Monday for Labor Day.

Three market winners are about to gain a powerful catalyst

Illumina, Inc. (NASDAQ:ILMN) and Everpure, Inc. (NYSE:P) are set to join the S&P 500 as part of the index’s quarterly rebalancing, with the changes taking effect before the market opens on September 21. Both companies will replace Builders FirstSource and The Trade Desk. Both companies are moving up from the S&P MidCap 400. The change […]

Illumina (ILMN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AI energy play Bloom Energy will be added to the S&P 500 index on Sept. 21. Illumina and Everpure also will join. The three stocks rose.

Illumina stock has delivered a very strong 1 year return, yet its valuation checks pull in different directions, with an intrinsic value estimate pointing to upside while market based multiples suggest the shares are not cheap. The result is a stock that has re-rated sharply without a clear consensus on whether the current price offers much room for error. Illumina has returned 120.6% over the past year, which puts extra focus on whether recent gains already reflect optimistic...

In September 2026, Novacyt S.A. announced it had entered into a five-year Master Collaboration Agreement with Illumina, creating a framework for separate project-based deals in product development and commercial collaboration. This structure gives Illumina a flexible way to tap Novacyt’s complementary expertise without committing upfront capital to specific programs, potentially broadening future genomic applications. We’ll now examine how this new Master Collaboration framework with...

S&P said on Friday that Bloom Energy, Everpure (P) and Illumina (ILMN) will join the S&P 500 index.

The is getting three new members this month, with Bloom Energy Everpure and Illumina joining the benchmark as part of its latest quarterly reshuffle. Bloom Energy, which makes fuel-cell systems that provide on-site electricity to businesses and data centers, will replace Molson Coors Beverage the brewer behind brands including Coors Light and Miller Lite. Illumina, a maker of DNA-sequencing and genomic-analysis technology, will replace Builders FirstSource which supplies building materials and manufactured components to the U.S. residential-construction industry.

Investing.com -- Shares of Bloom Energy Corp., Illumina Inc., and Everpure Inc. rallied in extended trading Friday following news that all three companies will be added to the benchmark S&P 500 index. The reshuffling, announced by S&P Dow Jones Indices, forms part of a broader quarterly rebalance designed to ensure index constituents remain representative of their respective market capitalization tiers. Bloom Energy led the late-session advance, surging 7.5% after hours, while Illumina gained 2%

TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.

Looking back on life sciences tools & services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Illumina (NASDAQ:ILMN) and its peers.

Illumina (ILMN) has entered a new US$1.0b senior unsecured five year revolving credit facility that replaces its prior agreement, giving the company fresh financing flexibility without any current borrowings reported under the line. Illumina’s new revolving credit facility arrives during a strong run in the stock, with a 7 day share price return of 19.49% and a 90 day share price return of 49.82%. The 1 year total shareholder return of 127.88% contrasts with a 5 year total shareholder return...

Illumina (NasdaqGS: ILMN) has entered into a new US$1b unsecured revolving credit facility, replacing its previous agreement. The new facility provides updated covenants and increased flexibility for Illumina's future financing plans. The credit line is expected to serve as a liquidity backstop and support the company's broader capital structure decisions. Consider reviewing other companies with meaningful financing flexibility and balance sheet capacity in related areas through 38 power...

Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not all of them carry the same risk.

While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Illumina, Qnity Electronics and nVent Electric lead Zacks' latest Strong Buy picks as markets eye inflation, rates and global risks.

Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.